(0.33%) 5 116.78 points
(0.32%) 38 363 points
(0.38%) 15 988 points
(-0.97%) $83.04
(5.56%) $2.03
(0.29%) $2 354.10
(0.42%) $27.65
(4.10%) $959.95
(-0.25%) $0.932
(-0.46%) $10.97
(-0.55%) $0.796
(1.66%) $93.40
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 7.46%
@ $51.67
発行日: 27 4月 2024 @ 03:47
リターン: 2.52%
前回のシグナル: 4月 27 - 02:43
前回のシグナル:
リターン: 0.24 %
Live Chart Being Loaded With Signals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 946 711 |
平均出来高 | 1.77M |
時価総額 | 11.89B |
EPS | $0 ( 2024-02-13 ) |
次の収益日 | ( $0.880 ) 2024-04-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.99 |
ATR14 | $1.156 (2.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Clancy Paul J | Buy | 403 | Common Stock |
2024-03-28 | Harrigan Edmund | Buy | 413 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-28 | Baker Bros. Advisors Lp | Buy | 543 | Common Stock |
2024-03-25 | Trotta Matteo | Buy | 21 868 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
79.26 |
Last 98 transactions |
Buy: 1 089 090 | Sell: 137 626 |
ボリューム 相関
Incyte Corp 相関
10 最も負の相関 | |
---|---|
APOP | -0.914 |
CMLF | -0.907 |
TYHT | -0.902 |
CPTA | -0.894 |
ICON | -0.893 |
EBSB | -0.892 |
GALT | -0.891 |
XPON | -0.886 |
SCR | -0.886 |
XLRN | -0.884 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Incyte Corp 相関 - 通貨/商品
Incyte Corp 財務諸表
Annual | 2023 |
収益: | $3.70B |
総利益: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2023 |
収益: | $3.70B |
総利益: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2022 |
収益: | $3.39B |
総利益: | $3.19B (93.90 %) |
EPS: | $1.530 |
FY | 2021 |
収益: | $2.99B |
総利益: | $2.84B (94.94 %) |
EPS: | $4.30 |
Financial Reports:
No articles found.
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。